Antitumor agents. 272. Structure-activity relationships and in vivo selective anti-breast cancer activity of novel neo-tanshinlactone analogues. 2010

Yizhou Dong, and Qian Shi, and Huei-Chen Pai, and Chieh-Yu Peng, and Shiow-Lin Pan, and Che-Ming Teng, and Kyoko Nakagawa-Goto, and Donglei Yu, and Yi-Nan Liu, and Pei-Chi Wu, and Kenneth F Bastow, and Susan L Morris-Natschke, and Arnold Brossi, and Jing-Yu Lang, and Jennifer L Hsu, and Mien-Chie Hung, and Eva Y-H P Lee, and Kuo-Hsiung Lee
Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina 27599, USA.

Neo-tanshinlactone (1) and its previously reported analogues, such as 2, are potent and selective in vitro antibreast cancer agents. The synthetic pathway to 2 was optimized from seven to five steps, with a better overall yield. Structure-activity relationships studies on these compounds revealed some key molecular determinants for this family of antibreast agents. Several derivatives (19-21 and 24) exerted potent and selective antibreast cancer activity with IC(50) values of 0.3, 0.2, 0.1, and 0.1 microg/mL, respectively, against the ZR-75-1 cell lines. Compound 24 was 2- to 3-fold more potent than 1 against SK-BR-3 and ZR-75-1. Importantly, 21 exhibited high selectivity; it was 23 times more active against ZR-75-1 than MCF-7. Compound 20 had an approximately 12-fold ratio of SK-BR-3/MCF-7 selectivity. In addition, analogue 2 showed potent activity against a ZR-75-1 xenograft model, but not PC-3 and MDA-MB-231 xenografts, as well as high selectivity against breast cancer cell line compared with normal breast tissue-derived cell lines. Further development of lead compounds 19-21 and 24 as clinical trial candidates is warranted.

UI MeSH Term Description Entries
D008297 Male Males
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D011753 Pyrones Keto-pyrans.
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D005260 Female Females
D005663 Furans Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran. Tetrahydrofurans
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

Yizhou Dong, and Qian Shi, and Huei-Chen Pai, and Chieh-Yu Peng, and Shiow-Lin Pan, and Che-Ming Teng, and Kyoko Nakagawa-Goto, and Donglei Yu, and Yi-Nan Liu, and Pei-Chi Wu, and Kenneth F Bastow, and Susan L Morris-Natschke, and Arnold Brossi, and Jing-Yu Lang, and Jennifer L Hsu, and Mien-Chie Hung, and Eva Y-H P Lee, and Kuo-Hsiung Lee
September 2006, Journal of medicinal chemistry,
Yizhou Dong, and Qian Shi, and Huei-Chen Pai, and Chieh-Yu Peng, and Shiow-Lin Pan, and Che-Ming Teng, and Kyoko Nakagawa-Goto, and Donglei Yu, and Yi-Nan Liu, and Pei-Chi Wu, and Kenneth F Bastow, and Susan L Morris-Natschke, and Arnold Brossi, and Jing-Yu Lang, and Jennifer L Hsu, and Mien-Chie Hung, and Eva Y-H P Lee, and Kuo-Hsiung Lee
November 2004, Journal of medicinal chemistry,
Yizhou Dong, and Qian Shi, and Huei-Chen Pai, and Chieh-Yu Peng, and Shiow-Lin Pan, and Che-Ming Teng, and Kyoko Nakagawa-Goto, and Donglei Yu, and Yi-Nan Liu, and Pei-Chi Wu, and Kenneth F Bastow, and Susan L Morris-Natschke, and Arnold Brossi, and Jing-Yu Lang, and Jennifer L Hsu, and Mien-Chie Hung, and Eva Y-H P Lee, and Kuo-Hsiung Lee
December 2010, Bioorganic & medicinal chemistry letters,
Yizhou Dong, and Qian Shi, and Huei-Chen Pai, and Chieh-Yu Peng, and Shiow-Lin Pan, and Che-Ming Teng, and Kyoko Nakagawa-Goto, and Donglei Yu, and Yi-Nan Liu, and Pei-Chi Wu, and Kenneth F Bastow, and Susan L Morris-Natschke, and Arnold Brossi, and Jing-Yu Lang, and Jennifer L Hsu, and Mien-Chie Hung, and Eva Y-H P Lee, and Kuo-Hsiung Lee
January 2017, Bioorganic & medicinal chemistry,
Yizhou Dong, and Qian Shi, and Huei-Chen Pai, and Chieh-Yu Peng, and Shiow-Lin Pan, and Che-Ming Teng, and Kyoko Nakagawa-Goto, and Donglei Yu, and Yi-Nan Liu, and Pei-Chi Wu, and Kenneth F Bastow, and Susan L Morris-Natschke, and Arnold Brossi, and Jing-Yu Lang, and Jennifer L Hsu, and Mien-Chie Hung, and Eva Y-H P Lee, and Kuo-Hsiung Lee
December 2019, Bioorganic & medicinal chemistry letters,
Yizhou Dong, and Qian Shi, and Huei-Chen Pai, and Chieh-Yu Peng, and Shiow-Lin Pan, and Che-Ming Teng, and Kyoko Nakagawa-Goto, and Donglei Yu, and Yi-Nan Liu, and Pei-Chi Wu, and Kenneth F Bastow, and Susan L Morris-Natschke, and Arnold Brossi, and Jing-Yu Lang, and Jennifer L Hsu, and Mien-Chie Hung, and Eva Y-H P Lee, and Kuo-Hsiung Lee
January 2011, Bioorganic & medicinal chemistry letters,
Yizhou Dong, and Qian Shi, and Huei-Chen Pai, and Chieh-Yu Peng, and Shiow-Lin Pan, and Che-Ming Teng, and Kyoko Nakagawa-Goto, and Donglei Yu, and Yi-Nan Liu, and Pei-Chi Wu, and Kenneth F Bastow, and Susan L Morris-Natschke, and Arnold Brossi, and Jing-Yu Lang, and Jennifer L Hsu, and Mien-Chie Hung, and Eva Y-H P Lee, and Kuo-Hsiung Lee
September 2004, Bioorganic & medicinal chemistry letters,
Yizhou Dong, and Qian Shi, and Huei-Chen Pai, and Chieh-Yu Peng, and Shiow-Lin Pan, and Che-Ming Teng, and Kyoko Nakagawa-Goto, and Donglei Yu, and Yi-Nan Liu, and Pei-Chi Wu, and Kenneth F Bastow, and Susan L Morris-Natschke, and Arnold Brossi, and Jing-Yu Lang, and Jennifer L Hsu, and Mien-Chie Hung, and Eva Y-H P Lee, and Kuo-Hsiung Lee
October 2004, Journal of medicinal chemistry,
Yizhou Dong, and Qian Shi, and Huei-Chen Pai, and Chieh-Yu Peng, and Shiow-Lin Pan, and Che-Ming Teng, and Kyoko Nakagawa-Goto, and Donglei Yu, and Yi-Nan Liu, and Pei-Chi Wu, and Kenneth F Bastow, and Susan L Morris-Natschke, and Arnold Brossi, and Jing-Yu Lang, and Jennifer L Hsu, and Mien-Chie Hung, and Eva Y-H P Lee, and Kuo-Hsiung Lee
June 1979, Journal of pharmaceutical sciences,
Yizhou Dong, and Qian Shi, and Huei-Chen Pai, and Chieh-Yu Peng, and Shiow-Lin Pan, and Che-Ming Teng, and Kyoko Nakagawa-Goto, and Donglei Yu, and Yi-Nan Liu, and Pei-Chi Wu, and Kenneth F Bastow, and Susan L Morris-Natschke, and Arnold Brossi, and Jing-Yu Lang, and Jennifer L Hsu, and Mien-Chie Hung, and Eva Y-H P Lee, and Kuo-Hsiung Lee
January 2017, European journal of medicinal chemistry,
Copied contents to your clipboard!